Skip to main content

Amphastar Pharmaceuticals Inc. Value Stock - Dividend - Research Selection

Amphastar pharmaceutical

ISIN: US03209R1032 , WKN: A11664

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company offers enoxaparin, a low molecular weight heparin that is used as an anticoagulant for the prevention and treatment of deep vein thrombosis; naloxone for opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures. It also provides lidocaine topical solution for various procedures; phytonadione injection for newborn babies; syringe products, such as morphine, atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; lorazepam injection for surgery and medical procedures; ketorolac for acute pain management; procainamide for documented ventricular arrhythmias; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy. In addition, the company manufactures and distributes recombinant human and porcine insulins. Further, it develops Primatene Mist, an over-the-counter epinephrine inhalation product candidate for the temporary relief of mild symptoms of intermittent asthma. Additionally, the company has a pipeline of 20 generic and proprietary product candidates in various stages of development for various indications. Its products are used in hospital or urgent care clinical settings, and primarily contracted and distributed through group purchasing organizations and drug wholesalers. Amphastar Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Rancho Cucamonga, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


After Protracted Sell-Off, Amphastar Looks Like A Value Pick

2025-09-23

A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Momentum

2025-09-09
Amphastar Pharmaceuticals (AMPH) is catching eyes this week as its share price saw a meaningful uptick over the past month. Investors might be wondering what is behind this shift, especially without a headline-making event driving the move. Sometimes, a stock’s quiet rally can signal changing sentiment or expectations about what lies ahead. For this reason, the recent swing is worth a closer look. For context, Amphastar’s performance has been a mixed bag. While shares have climbed 23% in the...

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack

2025-09-05
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 - Slideshow

2025-09-04
The following slide deck was published by Amphastar Pharmaceuticals, Inc.

Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?

2025-09-02
Investors need to pay close attention to AMPH stock based on the movements in the options market lately.

Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection

2025-09-02
We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Amphastar Pharmaceuticals, Inc. stands eighth among them. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a California-based company specializing in complex generics and proprietary medicines, is strengthening its position in the pharmaceutical market with major manufacturing and product expansion initiatives. A […]

Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference

2025-08-28
RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat ...

PJP: Healthcare Dashboard For August

2025-08-18
Discover top healthcare investment insights! Learn about Invesco Pharmaceuticals ETF, a top performer in the field. Click for more on PJP.

5 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call

2025-08-14
Amphastar Pharmaceuticals delivered a mixed second quarter, with management highlighting BAQSIMI’s strong sales momentum as a key driver amid ongoing pressures in legacy products. While the company’s non-GAAP profitability was above expectations, management pointed to increased competition in glucagon and epinephrine lines as factors behind revenue softness and margin compression. CFO William J. Peters explained, “We’re proud to share that while revenue was impacted by increased competition in o

Amphastar and Anji make licence agreement for three new peptides

2025-08-13
Over its lifetime, the partnership could yield $453m in total payments to Anji.